Table 2

Comparative analysis of gene expression changes in primary and metastatic melanoma.

    Gene Symbol

    Relative increase in gene expression

    Gene Symbol

    Relative decrease in gene expression


MIS to Thin

Thin To IM

IM to Thick

Thick to Met

MIS to Met

MIS to Thin

Thin To IM

IM to Thick

Thick to Met

MIS to Met


MAGEA2

<2

8.6

    9.4

3.1

30.7

SPRR1A

<2

<2

<2

    129.4

239.3

MAGEA3

<2

8.1

    10.7

3

83.8

SPRR1B

<2

<2

<2

    52.8

100.8

MAGE A6

<2

7.1

    9.8

2.7

103

KRT16

<2

<2

<2

    68.3

195.5

MAGEA1,2

<2

2.5

    8.9

2.6

81.5

KRT17

<2

2.6

<2

    27.4

57.6

MAGE A1

<2

<2

    11.1

<2

25.4

KRT6B

<2

<2

<2

    39.7

100.9

MAGE A5

<2

2.2

    3.9

<2

11.7

AQP3

<2

<2

3.2

    6.1

43.2

MMP19

    5.4

<2

<2

<2

7.4

CD24

<2

<2

2

    4.4

18.7

PDGFRL

    22.3

3.6

<2

<2

6.3

FLG

<2

<2

3

    24.1

140

C16orf34

    5.4

<2

<2

<2

18.5

IVL

<2

2.2

<2

    13.9

84.1

CTH

    3.9

<2

<2

<2

8.8

KLK7

<2

<2

6.5

    8.9

128

GPR19

    4.2

<2

3

<2

23.9

LGALS7

<2

<2

3.4

    17.3

109.3

SPP1

<2

    13.1

<2

<2

44.9

LOR

<2

<2

2.4

    22.6

120.4

HOXA10

<2

    3.3

<2

<2

3.8

RAB25

<2

<2

3.3

    10.3

88.4

MMP14

<2

    3.6

<2

2.1

9

SFN

<2

<2

<2

    10.6

24.2

AKT3

<2

<2

    7.5

<2

14.3

C19orf33

3.1

<2

4.6

    13.3

220.3

BCL2A1

<2

2.2

    4.8

<2

18.7

ASAH3

<2

<2

    25.9

<2

60

BIRC5

<2

<2

    3.7

<2

3.4

KRT15

<2

<2

    27.1

2.2

104.9

BUB1

<2

<2

    9.4

<2

10.8

ELOVL4

<2

2.3

    14.7

<2

41.9

CDC45L

<2

<2

    13

<2

9.1

GATA3

2.5

<2

    14.3

<2

23.5

CDK2

<2

<2

    4.8

<2

8.4

MUC15

<2

2.2

    11.9

<2

25

CSAG2

<2

<2

    19.6

2.6

54.5

SCEL

<2

<2

    28.8

<2

71.8

DUSP4

2

<2

    5.7

<2

12.5

TP73L

<2

<2

    5.5

3.4

41.2

DUSP6

<2

<2

    3.7

<2

10.5

RORA

<2

<2

    6.2

2.2

26.6

GYPC

<2

<2

    12.2

<2

14.2

POU2F3

<2

<2

    13.9

2.2

73.9

HEY1

<2

<2

    5.7

<2

9.3

ICEBERG

<2

2.7

    6.7

4.5

32.3

KIFC1

<2

<2

    10.4

<2

16

CASZ1

<2

    4.8

2.8

<2

12.3

PEG10

<2

2.4

    4.1

<2

11.3

HR

<2

    3.7

<2

<2

7.7

RASGRF1

<2

<2

    5.1

<2

9.9

TMPRSS4

    8.7

<2

<2

3.1

42

RGS20

3.4

<2

    9.2

<2

34.3

STAR

    4.9

<2

<2

<2

11.1

SLC16A4

<2

<2

    4.4

<2

26.4

ST7L

    4.3

<2

3.6

<2

8.4

SOX5

<2

<2

    12.3

<2

19.8

LTB4R

    4

<2

2.3

<2

9.9

TRIM51

<2

3.1

    15.9

<2

63.6

HAS3

    4.9

<2

<2

2.5

16.6

TYMS

<2

<2

    3.6

<2

4.7

FGFR3

    3.9

<2

3.2

<2

7.6


NOTE: All annotated genes listed above with a < 2 indicates that any difference between tumors for each comparative analysis was less than 2-fold. Underlined numbers indicate the greatest change in gene expression across varying PCM tumor thickness for each gene. Abbreviations: MIS, melanoma-in-situ, Thin, thin melanomas < 1.0 mm in Breslow's thickness, I.M., intermediate thickness between 1–4 mm, with thick melanomas > 4 mm. PCM, primary cutaneous melanoma.

Riker et al. BMC Medical Genomics 2008 1:13   doi:10.1186/1755-8794-1-13

Open Data